 |
29 Products |  |
56 Diseases | | 29 Products |
|
154 Trials |  |
7457 News |  |
| «12...86878889909192939495969798» |
- ||| Milprosa (progesterone vaginal ring) / Ferring
New P1 trial: A Pharmacokinetic Study to Evaluate the Bioequivalence of 2 Progesterone Vaginal Rings in Postmenopausal Women (clinicaltrials.gov) - Mar 18, 2014
P1, N=56, Recruiting, Sponsor: Teva Branded Pharmaceutical Products, R&D Inc.
- || Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment change, HEOR, Patient reported outcomes: Health-related Quality of Life and Patient-reported Outcomes in Rheumatoid Arthritis Patients Treated With Certolizumab Pegol (clinicaltrials.gov) - Mar 17, 2014
P=N/A, N=81, Completed, Sponsor: UCB Pharma SA
N=105 --> 81
- ||| Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion, HEOR, Patient reported outcomes: Health-related Quality of Life and Patient-reported Outcomes in Rheumatoid Arthritis Patients Treated With Certolizumab Pegol (clinicaltrials.gov) - Mar 17, 2014
P=N/A, N=81, Completed, Sponsor: UCB Pharma SA
N=105 --> 81 Active, not recruiting --> Completed
- Xtandi (enzalutamide capsule) / Pfizer, Astellas, Mekinist (trametinib) / Novartis, BeiGene, Firmagon (degarelix) / Astellas, Ferring
Trial initiation date: Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer (clinicaltrials.gov) - Mar 16, 2014
P2, N=45, Not yet recruiting, Sponsor: University of California, Los Angeles
Active, not recruiting --> Completed Initiation date: Dec 2013 --> May 2014
- ||||||| Menopur (menotropin) / Ferring, Bravelle (urofollitropin) / Ferring
Trial completion: Effect of a Higher Than Maximum 450IU Gonadotropin Dose in an In-vitro Fertilization Cycle (clinicaltrials.gov) - Mar 11, 2014
P3, N=366, Completed, Sponsor: OVO R & D
Initiation date: Dec 2013 --> May 2014 Active, not recruiting --> Completed
- Firmagon (degarelix) / Astellas, Ferring
Clinical: Long Acting GnRH Antagonist in PCOS Women Undergoing IVF (clinicaltrials.gov) - Mar 10, 2014
P=N/A, N=20, Recruiting, Sponsor: Bioroma
- ||| Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment closed, Combination therapy: SPEED: Open Label Study to Assess the Predictability of Early Response to Certolizumab Pegol in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Mar 6, 2014
P4, N=120, Active, not recruiting, Sponsor: UCB, Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||| Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment change: Pediatric Arthritis Study of Certolizumab Pegol (clinicaltrials.gov) - Mar 5, 2014
P3, N=156, Recruiting, Sponsor: UCB BIOSCIENCES GmbH
Recruiting --> Active, not recruiting N=125 --> 156
- |||||| Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment open: Pediatric Arthritis Study of Certolizumab Pegol (clinicaltrials.gov) - Mar 5, 2014
P3, N=156, Recruiting, Sponsor: UCB BIOSCIENCES GmbH
N=125 --> 156 Active, not recruiting --> Recruiting
- Orencia (abatacept) / BMS, Rituxan (rituximab) / Roche
Trial initiation date: SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug. (clinicaltrials.gov) - Mar 4, 2014
P4, N=477, Recruiting, Sponsor: Julia Brown
Active, not recruiting --> Recruiting Initiation date: Mar 2011 --> Aug 2011
- Orencia (abatacept) / BMS, Rituxan (rituximab) / Roche
Enrollment change: SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug. (clinicaltrials.gov) - Mar 4, 2014
P4, N=477, Recruiting, Sponsor: Julia Brown
Initiation date: Mar 2011 --> Aug 2011 N=870 --> 477
- Orencia (abatacept) / BMS, Rituxan (rituximab) / Roche
Enrollment open: SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug. (clinicaltrials.gov) - Mar 4, 2014
P4, N=477, Recruiting, Sponsor: Julia Brown
N=870 --> 477 Not yet recruiting --> Recruiting
- Cimzia (certolizumab pegol) / Astellas, UCB
Biomarker, Enrollment change, IO biomarker, Immunomodulating, Biopsy: Rheumatoid Arthritis Treatment and Biopsy Study Assessing Certolizumab Pegol (Cimzia) (clinicaltrials.gov) - Feb 25, 2014
P3, N=12, Completed, Sponsor: Nathan Wei, MD, FACP, FACR:
Not yet recruiting --> Recruiting N=10 --> 12
- Cimzia (certolizumab pegol) / Astellas, UCB
Biomarker, Trial completion, IO biomarker, Immunomodulating, Biopsy: Rheumatoid Arthritis Treatment and Biopsy Study Assessing Certolizumab Pegol (Cimzia) (clinicaltrials.gov) - Feb 25, 2014
P3, N=12, Completed, Sponsor: Nathan Wei, MD, FACP, FACR:
N=10 --> 12 Recruiting --> Completed
- ||||||| Firmagon (degarelix) / Astellas, Ferring
Trial completion: Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer (clinicaltrials.gov) - Feb 22, 2014
P2/3, N=57, Completed, Sponsor: Ferring Pharmaceuticals
Recruiting --> Completed Active, not recruiting --> Completed
- |||| Firmagon (degarelix) / Astellas, Ferring
Trial completion: A Comparative Study of Degarelix Three-month Depot in Three Different Dosing Regimens in Patients With Prostate Cancer (clinicaltrials.gov) - Feb 22, 2014
P2, N=460, Completed, Sponsor: Ferring Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Menopur (menotropin) / Ferring, Orgalutran (ganirelix acetate) / Organon, Follistim AQ Cartridge (follitropin beta) / Organon
New P4 trial: Efficacy of Recombinant FSH/GnRH Antagonist Protocol With and Without LH Adjunct for Egg Bank Donation (clinicaltrials.gov) - Feb 20, 2014
P4, N=50, Not yet recruiting, Sponsor: Michigan Reproductive Medicine
- ||| Menopur (menotropin) / Ferring
Trial completion: Post Marketing Surveillance of MENOPUR (clinicaltrials.gov) - Feb 19, 2014
P=N/A, N=2501, Completed, Sponsor: Ferring Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Completed
- | Lutrelef (gonadorelin acetate) / Ferring
Enrollment open: LutrePulse Hypogonadotropic Hypogonadism (clinicaltrials.gov) - Feb 12, 2014
P3, N=36, Recruiting, Sponsor: Ferring Pharmaceuticals
Recruiting --> Completed Not yet recruiting --> Recruiting
- | Glypressin (terlipressin) / Ferring
New P4 trial: Terli-NGAL: Perioperative Evaluation of Terlipressin Infusion During Living Donor Liver Transplantation on Incidence of Acute Kidney (clinicaltrials.gov) - Feb 9, 2014
P4, N=25, Recruiting, Sponsor: National Liver Institute, Egypt
- ||| Menopur (menotropin) / Ferring
Enrollment open: An Explorative Prospective Observational Study to Describe Morphokinetic De-selection Parameters in Human Embryos (clinicaltrials.gov) - Feb 6, 2014
P=N/A, N=700, Recruiting, Sponsor: Ferring Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Adstiladrin (nadofaragene firadenovec-vncg) / Ferring
Enrollment closed: Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer (clinicaltrials.gov) - Feb 5, 2014
P2, N=40, Active, not recruiting, Sponsor: FKD Therapies Oy
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || Goofice (elobixibat) / Eisai, Mochida, Ipsen
Trial suspension: Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation (clinicaltrials.gov) - Jan 28, 2014
P3, N=840, Suspended, Sponsor: Ferring Pharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Suspended
- || Goofice (elobixibat) / Eisai, Mochida, Ipsen
Trial suspension: 26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation (clinicaltrials.gov) - Jan 28, 2014
P3, N=840, Suspended, Sponsor: Ferring Pharmaceuticals
Recruiting --> Suspended Recruiting --> Suspended
- Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment closed: NIMRA: Novel Imaging Markers for Rheumatoid Arthritis (clinicaltrials.gov) - Jan 14, 2014
P4, N=20, Active, not recruiting, Sponsor: University of California, San Francisco
Recruiting --> Suspended Not yet recruiting --> Active, not recruiting
- || Cervidil (dinoprostone) / Ferring
New P3 trial: Titrated Oral Misoprostol Compared to Vaginal Dinoprostone for Induction of Labor (clinicaltrials.gov) - Jan 13, 2014
P3, N=200, Recruiting, Sponsor: Ain Shams University
- Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment open: CRIB: A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta (clinicaltrials.gov) - Jan 13, 2014
P1, N=20, Recruiting, Sponsor: UCB BIOSCIENCES, Inc.
Not yet recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Euflexxa (hyaluronic acid) / Ferring
Enrollment open, MRI: To Look at the Characteristics of Synovial Fluid and Cartilage Matrix in Osteoarthritic Knee After Hyaluronic Acid Injection (clinicaltrials.gov) - Jan 13, 2014
P4, N=12, Recruiting, Sponsor: University of California, San Francisco
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Cervidil (dinoprostone) / Ferring
Enrollment open: Titrated Oral Misoprostol Compared to Vaginal Dinoprostone for Induction of Labor (clinicaltrials.gov) - Jan 12, 2014
P3, N=200, Recruiting, Sponsor: Ain Shams University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Rebyota (fecal microbiota, live-jslm) / Ferring
Enrollment closed: Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea (clinicaltrials.gov) - Jan 8, 2014
P2, N=40, Active, not recruiting, Sponsor: Rebiotix Inc.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||||| Firmagon (degarelix) / Astellas, Ferring, Yervoy (ipilimumab) / BMS
New P2 trial, Metastases: Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy (clinicaltrials.gov) - Dec 22, 2013
P2, N=53, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
- | Cimzia (certolizumab pegol) / Astellas, UCB
New P1 trial: CRIB: A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta (clinicaltrials.gov) - Dec 22, 2013
P1, N=20, Recruiting, Sponsor: UCB BIOSCIENCES, Inc.
- ||| Zomacton (somatropin) / Ferring
Adherence: ZOMAXEPT: Evaluation of the Adherence and the Patient Acceptability of Zomacton (clinicaltrials.gov) - Dec 19, 2013
P=N/A, N=90, Not yet recruiting, Sponsor: Ferring Pharmaceuticals
- |||||||||| Firmagon (degarelix) / Astellas, Ferring
New P3 trial: An Extension Long-term Safety and Tolerability Trial of Degarelix in Chinese Patients With Prostate Cancer (clinicaltrials.gov) - Dec 17, 2013
P3, N=220, Enrolling by invitation, Sponsor: Ferring Pharmaceuticals
- |||||| Firmagon (degarelix) / Astellas, Ferring
Enrollment open: An Extension Long-term Safety and Tolerability Trial of Degarelix in Chinese Patients With Prostate Cancer (clinicaltrials.gov) - Dec 12, 2013
P3, N=220, Enrolling by invitation, Sponsor: Ferring Pharmaceuticals
Recruiting --> Active, not recruiting Not yet recruiting --> Enrolling by invitation
- Firmagon (degarelix) / Astellas, Ferring
New P2 trial: TRial on the Endocrine Activity of Neoadjuvant Degarelix (clinicaltrials.gov) - Dec 5, 2013
P2, N=50, Not yet recruiting, Sponsor: International Breast Cancer Study Group
- ||||| Firmagon (degarelix) / Astellas, Ferring
New P2 trial: GETUG-AFU22: Comparison of HT Concomitant With RT vs RT Alone in Patients With a Detectable PSA After Prostatectomy (clinicaltrials.gov) - Nov 21, 2013
P2, N=120, Recruiting, Sponsor: UNICANCER
- Xtandi (enzalutamide capsule) / Pfizer, Astellas, Mekinist (trametinib) / Novartis, BeiGene, Firmagon (degarelix) / Astellas, Ferring
New P2 trial: Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer (clinicaltrials.gov) - Nov 19, 2013
P2, N=45, Not yet recruiting, Sponsor: University of California, Los Angeles
- || Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment change: Cimzia Treatment in Rheumatoid Arthritis: Randomizing to Stop Versus Continue Disease-modifying Anti-rheumatic Drug(s) (clinicaltrials.gov) - Nov 13, 2013
P=N/A, N=125, Recruiting, Sponsor: Pope Research Corporation
Not yet recruiting --> Enrolling by invitation N=300 --> 125
- Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment closed: Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate (clinicaltrials.gov) - Nov 12, 2013
P4, N=892, Active, not recruiting, Sponsor: UCB Pharma SA
N=300 --> 125 Recruiting --> Active, not recruiting
- ||| Lutrelef (gonadorelin acetate) / Ferring
New P3 trial: LutrePulse Hypogonadotropic Hypogonadism (clinicaltrials.gov) - Nov 4, 2013
P3, N=36, Recruiting, Sponsor: Ferring Pharmaceuticals
- ||||| Testavan (transdermal testosterone gel 2%) / Ferring
Enrollment change: A Multicenter Extension Trial to Evaluate the Safety of Testosterone Gel (clinicaltrials.gov) - Oct 30, 2013
P3, N=145, Completed, Sponsor: Ferring Pharmaceuticals
Recruiting --> Active, not recruiting N=200 --> 145
- ||||||| Testavan (transdermal testosterone gel 2%) / Ferring
Trial completion: A Multicenter Extension Trial to Evaluate the Safety of Testosterone Gel (clinicaltrials.gov) - Oct 30, 2013
P3, N=145, Completed, Sponsor: Ferring Pharmaceuticals
N=200 --> 145 Enrolling by invitation --> Completed
- |||||| Bravelle (urofollitropin) / Ferring
Enrollment open, Head-to-Head: Evaluation of Efficacy and Safety of Highly Purified Urofollitropin in Chinese Females Undergoing an Assisted Reproductive Technology (ART) Program (clinicaltrials.gov) - Oct 27, 2013
P3, N=200, Recruiting, Sponsor: Ferring Pharmaceuticals
Enrolling by invitation --> Completed Not yet recruiting --> Recruiting
- |||||| Bravelle (urofollitropin) / Ferring
Enrollment open, Head-to-Head: Evaluation of Efficacy and Safety of Highly Purified Urofollitropin for Ovulation Induction in Chinese Females (clinicaltrials.gov) - Oct 22, 2013
P3, N=180, Recruiting, Sponsor: Ferring Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || Pentasa (mesalamine) / Ferring, Takeda
Enrollment change: Tolerability of Pentasa Sachet in Patients With Ulcerative Colitis (clinicaltrials.gov) - Oct 17, 2013
P=N/A, N=568, Completed, Sponsor: Ferring Pharmaceuticals
Not yet recruiting --> Recruiting N=900 --> 568
- |||||| Rekovelle (follitropin delta) / Ferring
Enrollment open: ESTHER-2: Evidence-based Stimulation Trial With Human rFSH in Europe and Rest of World 2 (clinicaltrials.gov) - Oct 17, 2013
P3, N=400, Enrolling by invitation, Sponsor: Ferring Pharmaceuticals
N=900 --> 568 Not yet recruiting --> Enrolling by invitation
- ||| Pentasa (mesalamine) / Ferring, Takeda
Trial completion: Tolerability of Pentasa Sachet in Patients With Ulcerative Colitis (clinicaltrials.gov) - Oct 17, 2013
P=N/A, N=568, Completed, Sponsor: Ferring Pharmaceuticals
Not yet recruiting --> Enrolling by invitation Active, not recruiting --> Completed
- |||||| Rekovelle (follitropin delta) / Ferring
Enrollment open: ESTHER-1: Evidence-based Stimulation Trial With Human rFSH in Europe and Rest of World 1 (clinicaltrials.gov) - Oct 16, 2013
P3, N=1150, Recruiting, Sponsor: Ferring Pharmaceuticals
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||||||||| Firmagon (degarelix) / Astellas, Ferring
New P3 trial: A Study to Compare the Effect of ASP3550 With Goserelin in Patients With Prostate Cancer (clinicaltrials.gov) - Oct 15, 2013
P3, N=230, Recruiting, Sponsor: Astellas Pharma Inc